Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the ...

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an ...

Jefferies isn’t sweating Eli Lilly’s slightly slimmer projections for its weight-loss drug Orfo, maintaining a spicy $1,020 ...

Weight loss “wonder drug” Wegovy will cost Irish users around €220 a month as it is not currently availably under either the ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

The medical sector is one of the major adopters of artificial intelligence (AI), which is currently being used to synthesize ...